Gov. Perdue Among Speakers At CED’s Biotech 2010

CED, formerly the Council for Entrepreneurial Development (www.cednc.org), a private, nonprofit organization that promotes entrepreneurial efforts in the Triangle region of North Carolina, has announced the complete slate of speakers scheduled for CED’s Biotech 2010 conference, to be held Monday, Feb. 22 through Tuesday, Feb. 23 at the Raleigh Convention Center, located at 500 South Salisbury Street in Raleigh. Speakers include North Carolina Governor Bev Perdue; Steve Krognes, senior vice president and chief financial officer at Genentech, Inc., who orchestrated the largest biotechnology merger in history; and Talecris Chairman and CEO Larry D. Stern, who oversaw Talecris’ initial public offering in 2009, the year’s largest biotechnology IPO. Randall Marcuson, former Embrex, Inc. president and CEO, will receive the 2010 CED Biotechnology Leadership Award.

CED will present its 19th annual Biotech conference in partnership with the North Carolina Biotechnology Center (www.ncbiotech.org) and North Carolina Biosciences Organization (www.ncbioscience.org). The early registration deadline for the conference now is set for Thursday, Jan. 28 at 5 p.m.

QUOTES:
"We are fortunate to have a remarkable lineup of speakers at CED’s Biotech 2010," said CED president Joan Siefert Rose. "They represent some of the brightest minds in the biotechnology and pharmaceutical industries today, and we look forward to receiving their insight."

NEW MEDIA CONTENT:
CED blog
http://cednc.wordpress.com

CED Twitter page
http://twitter.com/CEDNC

DETAILS:
- Governor Perdue and Steve Krognes are joined by fellow keynote speakers Ernest Mario, Ph.D., chairman and CEO of Capnia; Louis G. Lange, M.D., Ph.D., general partner at Asset Management and former chairman, CEO and CSO of CV Therapeutics, Inc.; and Allen D. Roses, MD, FRCP, director at Duke University’s Deane Drug Discovery Institute.

- Dr. Charles Hamner will present the 2010 CED Biotechnology Leadership Award to Randall Marcuson.

- Stephen Stefano, author of Passion and ICE and former senior vice president at GlaxoSmithKline, will moderate a panel session, "The Impact of Healthcare Reforms on Biotech," which will include Lanier M. Cansler, N.C. Department of Health and Human Services Secretary; Dr. Kevin Schulman, associate director of The Duke Clinical Research Institute, professor of medicine at Duke University Medical Center and professor of business administration at Duke’s Fuqua School of Business; Anthony Y. Sun, partner at Aisling Capital; and J. Bradley Wilson, president and COO of Blue Cross and Blue Shield of North Carolina.

- Stephen Sands, vice chairman of U.S. investment banking and global co-head at Lazard, will moderate featured panel session "Financing in the Current Environment," featuring Larry Stern; John Clerici, partner and chair of the life sciences and public health preparedness practice at McKenna Long & Aldridge LLP; Ed Mathers, partner at NEA; and Dr. Lauren Silverman, managing director of Novartis Option Fund.

- A CEO panel, discussing "Leadership in Changing Times," will be moderated by Christy Shaffer, Ph.D., president and CEO of Inspire Pharmaceuticals and will include J. Donald deBethizy, Ph.D., president and CEO of Targacept, Inc.; Neal Fowler, CEO of Liquidia Technologies, Inc.; Michael Pearson, chairman and CEO of Valeant Pharmaceuticals International; and Jon Stonehouse, president and CEO of Biocryst Pharmaceuticals, Inc.

- The "Opportunities in Personalized Medicine" panel, moderated by Michael Stocum, managing director of Personalized Medicine Partners, LLC, will include Patrick F. Terry, co-founder of Genomic Health; Dr. Linda Harpole, vice president of global health outcomes at GlaxoSmithKline; Dr. Louis I. Hochheiser, medical director of clinical policy development at Humana; and Michael Rosenberg, CEO of Health Decisions, Inc.

- The "Opportunities and Challenges in Global Health" panel will be moderated by Nicole Fouché, executive director of the Triangle Global Health Consortium. The panel will feature Dr. Oren J. Cohen, chief medical and scientific officer at Quintiles Transnational Corp.; E. Wayne Holden, Ph.D., executive vice president of social, statistical and environmental sciences at RTI International; Robert E. Johnston, Ph.D., executive director of Global Vaccines, Inc.; Wayne Myers, director of public health informatics at SRA International, Inc.; and Jon Stonehouse, CEO of Biocryst Pharmaceuticals.

- Jeffrey Brennan, vice president of business and commercial development at Targacept, will moderate the final panel on the topic of licensing. It includes David Donabedian, Ph.D., vice president of strategic alliances of GlaxoSmithKline’s U.S. Centre of Excellence for External Drug Discovery; Mark A. Miller, Vice President of Corporate Business Development, Eli Lilly and Company and Bob Silverman, global licensing director of Hoffmann-La Roche, Inc.

- Biotech 2010 will feature two new program offerings. The North Carolina Biotechnology Center will host partnering meetings, designed for emerging biotech companies to match with leading pharmaceutical companies. More information and registration is available at www.cednc.org/partnering. Hoffman-La Roche Inc. will host Venture Day, a chance for an investor-only audience to take a look at the new drug development business model.

ABOUT CED:
CED (formerly The Council for Entrepreneurial Development) is a private, nonprofit organization founded in 1984 to identify, enable and promote high-growth, high-impact companies and accelerate the region’s entrepreneurial culture. Headquartered in the Research Triangle Park, CED is the oldest and largest entrepreneurial support organization in the nation with more than 5,500 active members. CED provides know-how, networking, mentoring and capital formation resources to new and existing high-growth entrepreneurs through annual conferences, programs and web-based resources. CED has helped entrepreneurs, investors, service partners, researchers and public policy makers in diverse emerging industries and at all stages of development – from high-tech, production-based organizations to service companies, from one-person start-ups to 1000-person businesses. Visit www.cednc.org for more information.

Jake Potter
MMI Public Relations
(919) 233-6600
jake@mmipublicrelations.com
http://twitter.com/MMIPR
www.mmipublicrelations.com

(end)